臺灣博碩士論文加值系統

第一章 緒論 01
（一） 代謝症候群 01
（二） 慢性血管病變 03
（三） 血管新生 04
（四） 內皮前驅細胞 06
（五） 血管內皮生長因子 09
（六） 發炎反應 12
（七） 腫瘤壞死因子-α 14
（八） 高血糖 15
（九） 一氧化氮 17
（十） 環氧化酶 20
（十一） 活性氧物質 22
第二章 研究目的 24
第三章 研究材料與方法 25
第一節 研究材料 25
（一） 細胞株 25
（二） 天然物WJO00及其結構衍生物 30
（三） 試藥 31
（四） 抗體 33
（五） 儀器 34
第二節 實驗方法 35
（一） 細胞毒性試驗 36
（二） 血管新生試驗 39
（三） 西方轉漬 43
（四） 一氧化氮試驗 46
（五） 活性氧試驗 48
第四章 研究結果 50
（一） 天然物WJO00及其結構衍生物對於人類內皮前驅細胞之
細胞毒性 50
（二） 天然物WJO00及其結構衍生物對於人類內皮前驅細胞血
管新生之影響 52
（三） 不同濃度之天然物WJO00及其結構衍生物對於人類內皮
前驅細胞血管新生之影響 54
（四） 天然物WJO00及其結構衍生物經由血管內皮生長因子路
徑影響人類內皮前驅細胞血管新生 56
（五） 不同濃度之天然物WJO00及其結構衍生物經由血管內皮
生長因子路徑影響人類內皮前驅細胞血管新生 58
（六） 不同濃度之天然物WJO00及其結構衍生物影響人類內皮
前驅細胞增生及血管新生之路徑 60
（七） 天然物WJO00及其結構衍生物誘導人類內皮前驅細胞產
生NO及eNOS蛋白質表現 62
（八） TNF-α和D-glucose對於人類內皮前驅細胞血管新生之影
響 64
（九） 在模擬慢性發炎的情況下天然物WJO00及其結構衍生物
對於人類內皮前驅細胞之細胞毒性 66
（十） 在模擬慢性發炎的情況下天然物WJO00及其結構衍生物
對於人類內皮前驅細胞血管新生之影響 68
（十一） 在模擬慢性發炎的情況下不同濃度之天然物WJO00及其
結構衍生物對於人類內皮前驅細胞血管新生之影響 70
（十二） 在模擬慢性發炎的情況下天然物WJO00及其結構衍生物
誘導人類內皮前驅細胞產生NO及抑制iNOS表現 72
（十三） 在模擬慢性發炎的情況下天然物WJO00及其結構衍生物
抑制人類內皮前驅細胞COX-2表現 74
（十四） 在模擬慢性發炎的情況下天然物WJO00及其結構衍生物
抑制人類內皮前驅細胞產生ROS 76
第五章 討論 78
（一） 細胞模式EPC的選用 78
（二） TNF-α與D-glucose的濃度 80
（三） 天然物WJO00及其結構衍生物促進血管新生之相關路徑
之探討 82
（四）天然物WJO00及其結構衍生物對於血管支架之應用 84
（五）天然物WJO00及其結構衍生物之未來其他發展 87
第六章 結論 88
第七章 參考文獻 89

1.Grundy, S.M. Drug therapy of the metabolic syndrome: minimizing the emerging crisis in polypharmacy. Nature reviews. Drug discovery 5, 295-309 (2006).
2.Jialal, I. Endothelial progenitor cell status in metabolic syndrome. Metabolic syndrome and related disorders 8, 193-195 (2010).
3.Brandes, R.P., Fleming, I. & Busse, R. Endothelial aging. Cardiovascular research 66, 286-294 (2005).
4.Yue, P.Y. et al. The angiosuppressive effects of 20(R)- ginsenoside Rg3. Biochemical pharmacology 72, 437-445 (2006).
5.Hristov, M., Erl, W. & Weber, P.C. Endothelial progenitor cells: mobilization, differentiation, and homing. Arteriosclerosis, thrombosis, and vascular biology 23, 1185-1189 (2003).
6.Bailey, A.S. & Fleming, W.H. Converging roads: evidence for an adult hemangioblast. Experimental Hematology 31, 987-993 (2003).
7.Jujo, K., Ii, M. & Losordo, D.W. Endothelial progenitor cells in neovascularization of infarcted myocardium. Journal of molecular and cellular cardiology 45, 530-544 (2008).
8.Asahara, T. Isolation of Putative Progenitor Endothelial Cells for Angiogenesis. Science 275, 964-966 (1997).
9.M. Nieda, A.N., P. D. Kendall, J. Sweetenham, B. Bradley, & J. Hows Endothelial cell precursors are normal components of human umbilical cord blood. British Journal of Haematology 98, 755-777 (1997).
10.Andreou, I., Tousoulis, D., Tentolouris, C., Antoniades, C. & Stefanadis, C. Potential role of endothelial progenitor cells in the pathophysiology of heart failure: clinical implications and perspectives. Atherosclerosis 189, 247-254 (2006).
11.Eguchi, M., Masuda, H. & Asahara, T. Endothelial progenitor cells for postnatal vasculogenesis. Clinical and experimental nephrology 11, 18-25 (2007).
12.Dimmeler, S. & Zeiher, A.M. Vascular repair by circulating endothelial progenitor cells: the missing link in atherosclerosis? J Mol Med (Berl) 82, 671-677 (2004).
13.N. Werner, G.N. Clinical and therapeeutical implications of EPC biology in atherosclerosis. Journal of Cellular and Molecular Medicine 10, 318-332 (2006).
14.J. M. Hill, G.Z., J.P.J. Halcox, W.H. Schenke, M. A. Waclawiw, A. A. Quyyumi, & T. Finkel Circulating Endothelial Progenitor Cells, Vascular Function, and Cardiovascular Risk. The New England Journal of Medicine 348, 593-600 (2003).
15.Shahin Rafii, D.L. Therapeutic stem and progenitor cell transplatation for organ vascularization and regeneration. Nature Medicine 9, 702-712 (2003).
16.Perticone, F. et al. Prognostic Significance of Endothelial Dysfunction in Hypertensive Patients. Circulation 104, 191-196 (2001).
17.Madeddu, P. et al. Transplantation of low dose CD34+KDR+ cells promotes vascular and muscular regeneration in ischemic limbs. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 18, 1737-1739 (2004).
18.Kawamoto, A. et al. Therapeutic Potential of Ex Vivo Expanded Endothelial Progenitor Cells for Myocardial Ischemia. Circulation 103, 634-637 (2001).
19.Badorff, C. Transdifferentiation of Blood-Derived Human Adult Endothelial Progenitor Cells Into Functionally Active Cardiomyocytes. Circulation 107, 1024-1032 (2003).
20.Keiko Naruse et al. Therapeutic Neovascularization Using Cord Blood - Derived Endothelial Progenitor Cells for Diabetic Neuropathy. Diabetes 54, 1823-1828 (2005).
21.Michael Klagsbrun & D''Amore, P.A. Vascular Endothelial Growth Factor and its Receptors. Cvtokine & Growth Factor Reviews 7, 259-270 (1996).
22.N. Ferrara, T.D.S. The Biology of Vascular Endothelial Growth Factor. Endocrine Reviews 18, 4-25 (1997).
23.Takahashi, H. & Shibuya, M. The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions. Clin Sci (Lond) 109, 227-241 (2005).
24.G. Neufeld, T.C., S. Gengrinovitch, & Z. Poltorak Vascular endothelial growth factor (VEGF) and its receptors. The FASEB Journal 13, 9-22 (1999).
25.Otrock, Z.K., Makarem, J.A. & Shamseddine, A.I. Vascular endothelial growth factor family of ligands and receptors: review. Blood cells, molecules & diseases 38, 258-268 (2007).
26.Rini, B.I. & Small, E.J. Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 23, 1028-1043 (2005).
27.Gosain, A. et al. Exogenous pro-angiogenic stimuli cannot prevent physiologic vessel regression. The Journal of surgical research 135, 218-225 (2006).
28.Galkina, E. & Ley, K. Immune and inflammatory mechanisms of atherosclerosis. Annual review of immunology 27, 165-197 (2009).
29.Co, D.O., Hogan, L.H., Il-Kim, S. & Sandor, M. T cell contributions to the different phases of granuloma formation. Immunology letters 92, 135-142 (2004).
30.Caballero, A.E. Endothelial Dysfunction in Obesity and Insulin Resistance: A Road to Diabetes and Heart Disease. Obesity Research 11, 1278-1289 (2003).
31.Ciro Tetta, G.C., Vittorio Modena, Chiara Di Vittorio, Corrado Baglioni Tumour necrosis factor in serum and synovial fluid of patients with active and severe rheumatoid arthritis. Amnals ofthe Rhewnatic Diseases 49, 665-667 (1990).
32.Brennan, F.M. & McInnes, I.B. Evidence that cytokines play a role in rheumatoid arthritis. The Journal of clinical investigation 118, 3537-3545 (2008).
33.Ridker, P.M. et al. Elevation of Tumor Necrosis Factor - and Increased Risk of Recurrent Coronary Events After Myocardial Infarction. Circulation 101, 2149-2153 (2000).
34.Ridker, P.M. Clinical Application of C-Reactive Protein for Cardiovascular Disease Detection and Prevention. Circulation 107, 363-369 (2003).
35.Nishikawa, T. et al. Impact of mitochondrial ROS production on diabetic vascular complications. Diabetes research and clinical practice 77 Suppl 1, S41-45 (2007).
36.Erika Toth, A.R., Janos Toth, Pawel M. Kaminski, Michael S. Wolin, Zsolt Bagi, & Akos Koller Contribution of polyol pathway to arteriolar dysfunction in hyperglycemia. Role of oxidative stress, reduced NO, and enhanced PGH2/TXA2 mediation. AJP - Heart and Circulatory Physiology 293, 3096-3104 (2007).
37.Pricci, F. et al. Oxidative stress in diabetes-induced endothelial dysfunction involvement of nitric oxide and protein kinase C. Free Radical Biology and Medicine 35, 683-694 (2003).
38.Xue Gao, H.Z., Ann Marie Schmidt, & Cuihua Zhang AGE/RAGE produces endothelial dysfunction in coronary arterioles in Type 2 diabetic mice. AJP - Heart and Circulatory Physiology 6, 491-498 (2008).
39.Gao, L. & Mann, G.E. Vascular NAD(P)H oxidase activation in diabetes: a double-edged sword in redox signalling. Cardiovascular research 82, 9-20 (2009).
40.Belay Tesfamariam, M.L.B., Daniel Deykin, & Richard A. Cohen Elevated Glucose Promotes Generation of Endothelium-derived Vasoconstrictor Prostanoids in Rabbit Aorta. Journal of Clinical Investigation 85, 929-932 (1990).
41.Creager, M.A., Luscher, T.F., Cosentino, F. & Beckman, J.A. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: Part I. Circulation 108, 1527-1532 (2003).
42.Du, X. et al. Insulin resistance reduces arterial prostacyclin synthase and eNOS activities by increasing endothelial fatty acid oxidation. The Journal of clinical investigation 116, 1071-1080 (2006).
43.Lance, J.B.V.P. Nitric Oxide, Invertebrates and Hemoglobin. American Zoology 41, 346-359 (2001).
44.Snait Tamir, Teresa deRojas-Walker & Aharon Gal Nitric Oxide Production in Relation to Spontaneous B-Cell Lymphoma and Myositis in SJL Mice. American Association for Cancer Research 55, 4391-4397 (1995).
45.R. M. J. Palmer, A.G.F., & S. Moncada Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 327, 524-526 (1987).
46.Astrid Parenti, L.M., Xiao-Lan Cui, Janice G. Douglas, John D. Hood, Harris J. Granger§, Fabrizio Ledda, & Marina Ziche Nitric Oxide Is an Upstream Signal of Vascular Endothelial Growth Factor-induced Extracellular Signal-regulated Kinase1⁄2 Activation in Postcapillary Endothelium. The Journal of Biological Chemistry 273, 4220–4226 (1998).
47.Namba, T. et al. Angiogenesis induced by endothelial nitric oxide synthase gene through vascular endothelial growth factor expression in a rat hindlimb ischemia model. Circulation 108, 2250-2257 (2003).
48.Forstermann, U. & Sessa, W.C. Nitric oxide synthases: regulation and function. European heart journal 33, 829-837, 837a-837d (2012).
49.Korkmaz, A. et al. Melatonin: an established antioxidant worthy of use in clinical trials. Mol Med 15, 43-50 (2009).
50.M. S. Racic, J.S., & C. H. Evans Nitric Oxide and Arthritis. Arthritis and Rheumatism 36, 1036-1044 (1993).
51.John MacMicking, Q.-w.X., & Carl Nathan Nitric Oxide and Macrophage Function. Annual Reviews Immunology 15, 323-350 (1997).
52.Richard A. Robbins, K.H., Dan Nelson, Etsuro Sato, Jeffrey C. Hoyt Nitric oxide, peroxynitrite, and lower respiratory tract inflammation. Immunopharmacology 48, 217-221 (2000).
53.Dubois et al. Cyclooxygenase in biology and disease. The FASEB Journal 12, 1063-1073 (1998).
54.Morita, I. Distinct functions of COX-1 and COX-2. Prostaglandins & other Lipid Mediators 68-69, 165-175 (2002).
55.Posadas, I. et al. Co-regulation between cyclo-oxygenase-2 and inducible nitric oxide synthase expression in the time-course of murine inflammation. Naunyn-Schmiedeberg''s Archives of Pharmacology 361, 98-106 (2000).
56.Palinski, W. United they go: conjunct regulation of aortic antioxidant enzymes during atherogenesis. Circulation research 93, 183-185 (2003).
57.Toshio Imanishi, H.T., & Takashi Akasaka Endothelial Progenitor Cells Dysfunction and Senescence: Contribution to Oxidative Stress. Current Cardiology Reviews 4, 275-286 (2008).
58.Cai, H. & Harrison, D.G. Endothelial Dysfunction in Cardiovascular Diseases: The Role of Oxidant Stress. Circulation research 87, 840-844 (2000).
59.Claudio Bordignon, Claudio Bordignon, Claudio Bordignon, Claudio Bordignon & Bordignon, C. Cell therapy: achievements and perspectives. Haematologica 84, 1110-1149 (1999).
60.Wu, X., Lensch, M.W., Wylie-Sears, J., Daley, G.Q. & Bischoff, J. Hemogenic endothelial progenitor cells isolated from human umbilical cord blood. Stem Cells 25, 2770-2776 (2007).
61.John O''Brien, I.W., Terry Orton, & Francois Pognan Investigation of the Alamar Blue (resazurin) fluorescent dye for the assessment of mammalian cell cytotoxicity. European Journal of Biochemistry 267, 5421-5426 (2000).
62.Duarte, M. et al. A quantitative resazurin assay to determinate the viability of Trichomonas vaginalis and the cytotoxicity of organic solvents and surfactant agents. Experimental parasitology 123, 195-198 (2009).
63.D. S. Grant, J.L.K., M. C. Kibbey, S. LaFlamme, P. D. Burbelo, A. L. Goldstein, & H. K. Kleinman Matrigel induces thymosin b4 gene in differentiating endothelial cells. Journal of Cell Science 108, 3685-3694 (1995).
64.D. S. Grant, D. S. Grant, D. S. Grant & D. S. Grant Scatter factor induces blood vessel formation in vivo. Proceedings of the National Academy of Sciences of the United States of America 90, 1937-1941 (1993).
65.Xiu Ming Wang et al. A new microcellular cytotoxicity test based on calcein AM release. Human Immunology 37, 264-270 (1993).
66.Khoo, C.P., Micklem, K. & Watt, S.M. A comparison of methods for quantifying angiogenesis in the Matrigel assay in vitro. Tissue engineering. Part C, Methods 17, 895-906 (2011).
67.Tarpey, M.M., Wink, D.A. & Grisham, M.B. Methods for detection of reactive metabolites of oxygen and nitrogen: in vitro and in vivo considerations. American journal of physiology. Regulatory, integrative and comparative physiology 286, R431-444 (2004).
68.Carl P. LeBel, H.I., & Stephen C. Bondy Evaluation of the Probe 2'', 7''-Dichiorofluorescin as an Indicator of Reactive Oxygen Species Formation and Oxidative Stress. Chemical Research in Toxicology 5, 227-231 (1992).
69.Hur, J. et al. Characterization of two types of endothelial progenitor cells and their different contributions to neovasculogenesis. Arteriosclerosis, thrombosis, and vascular biology 24, 288-293 (2004).
70.Conover, C.A., Harrington, S.C. & Bale, L.K. Differential regulation of pregnancy associated plasma protein-A in human coronary artery endothelial cells and smooth muscle cells. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society 18, 213-220 (2008).
71.Atsushi Miura et al. Effect of tumor necrosis factor-a on insulin signal transduction in rat adipocytes: relation to PKCb and x translocation. Biochimica et Biophysica Acta 1449, 227-238 (1999).
72.Hui H. Zhang, Sudhesh Kumar, Anthony H. Barnett & Eggo, M.C. Tumour necrosis factor-a exerts dual effects on human adipose leptin synthesis and release. Molecular and Cellular Endocrinology 159, 79-88 (2000).
73.Meloche, S. & Pouyssegur, J. The ERK1/2 mitogen-activated protein kinase pathway as a master regulator of the G1- to S-phase transition. Oncogene 26, 3227-3239 (2007).
74.Lucia E. Rameh, L.C.C. The Role of Phosphoinositide 3-Kinase Lipid Products in Cell Function. The Journal of Biological Chemistry 274, 8347-8350 (1999).
75.Garg, S. & Serruys, P.W. Coronary stents: looking forward. Journal of the American College of Cardiology 56, S43-78 (2010).
76.Aoki, J. et al. Endothelial progenitor cell capture by stents coated with antibody against CD34: the HEALING-FIM (Healthy Endothelial Accelerated Lining Inhibits Neointimal Growth-First In Man) Registry. Journal of the American College of Cardiology 45, 1574-1579 (2005).
77.Blindt, R. et al. A novel drug-eluting stent coated with an integrin-binding cyclic Arg-Gly-Asp peptide inhibits neointimal hyperplasia by recruiting endothelial progenitor cells. Journal of the American College of Cardiology 47, 1786-1795 (2006).
78.Klomp, M., Beijk, M.A., Tijssen, J.G. & de Winter, R.J. One-year clinical outcome in an unselected patient population treated with the Genous endothelial progenitor cell capturing stent. Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions 77, 809-817 (2011).
79.Westerweel, P.E. et al. Endothelial progenitor cell levels in obese men with the metabolic syndrome and the effect of simvastatin monotherapy vs. simvastatin/ezetimibe combination therapy. European heart journal 29, 2808-2817 (2008).
80.Fadini, G.P. et al. Circulating endothelial progenitor cells are reduced in peripheral vascular complications of type 2 diabetes mellitus. Journal of the American College of Cardiology 45, 1449-1457 (2005).
81.Fadini, G.P. et al. Circulating CD34+ cells, metabolic syndrome, and cardiovascular risk. European heart journal 27, 2247-2255 (2006).
82.Salvemini, D. Regulation of cyclooxygenase enzymes by nitric oxide. Cellulat and Molecular Life Sciences 53, 576-582 (1997).
83.Gladding, P.A. et al. The antiplatelet effect of six non-steroidal anti-inflammatory drugs and their pharmacodynamic interaction with aspirin in healthy volunteers. The American journal of cardiology 101, 1060-1063 (2008).
84.Patrignani, P., Tacconelli, S., Sciulli, M.G. & Capone, M.L. New insights into COX-2 biology and inhibition. Brain research. Brain research reviews 48, 352-359 (2005).